228 related articles for article (PubMed ID: 19531681)
1. Tissue microarray validation: a methodologic study with special reference to lung cancer.
Karlsson C; Bodin L; Piehl-Aulin K; Karlsson MG
Cancer Epidemiol Biomarkers Prev; 2009 Jul; 18(7):2014-21. PubMed ID: 19531681
[TBL] [Abstract][Full Text] [Related]
2. Validation of tissue microarray technology in endometrioid cancer of the endometrium.
Fons G; Hasibuan SM; van der Velden J; ten Kate FJ
J Clin Pathol; 2007 May; 60(5):500-3. PubMed ID: 16822874
[TBL] [Abstract][Full Text] [Related]
3. Tissue microarray technology in the routine assessment of HER-2 status in invasive breast cancer: a prospective study of the use of immunohistochemistry and fluorescence in situ hybridization.
Graham AD; Faratian D; Rae F; Thomas JS
Histopathology; 2008 Jun; 52(7):847-55. PubMed ID: 18494613
[TBL] [Abstract][Full Text] [Related]
4. Comparison of automated cellular imaging system and manual microscopy for immunohistochemically stained cryostat sections of lung cancer specimens applying p53, ki-67 and p120.
Hilbe W; Gächter A; Duba HC; Dirnhofer S; Eisterer W; Schmid T; Mildner A; Bodner J; Wöll E
Oncol Rep; 2003; 10(1):15-20. PubMed ID: 12469137
[TBL] [Abstract][Full Text] [Related]
5. Postmenopausal status, hypertension and obesity as risk factors for malignant transformation in endometrial polyps.
Giordano G; Gnetti L; Merisio C; Melpignano M
Maturitas; 2007 Feb; 56(2):190-7. PubMed ID: 16963204
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of p53 and Ki-67 antigen expression in surgically treated non-small cell lung cancer: immunocytochemical detection with imprint cytology.
Maddau C; Confortini M; Bisanzi S; Janni A; Montinaro F; Paci E; Pontenani G; Rulli P; Salani A; Zappa M; Benvenuti A; Carozzi FM
Am J Clin Pathol; 2006 Mar; 125(3):425-31. PubMed ID: 16613347
[TBL] [Abstract][Full Text] [Related]
7. Tissue microarray-based immunohistochemical study can significantly underestimate the expression of HER2 and progesterone receptor in ductal carcinoma in situ of the breast.
Lin Y; Hatem J; Wang J; Quinn A; Hicks D; Tang P
Biotech Histochem; 2011 Oct; 86(5):345-50. PubMed ID: 20701550
[TBL] [Abstract][Full Text] [Related]
8. Validation of tissue microarray technology in vulvar cancer.
Fons G; van der Velden J; Burger M; ten Kate F
Int J Gynecol Pathol; 2009 Jan; 28(1):76-82. PubMed ID: 19047904
[TBL] [Abstract][Full Text] [Related]
9. Expression of p53, pRB, and p16 in lung tumours: a validation study on tissue microarrays.
Leversha MA; Fielding P; Watson S; Gosney JR; Field JK
J Pathol; 2003 Aug; 200(5):610-9. PubMed ID: 12898597
[TBL] [Abstract][Full Text] [Related]
10. Validation of tissue microarray technology in malignant peripheral nerve sheath tumours.
Cunha KS; Caruso AC; Gonçalves AS; Bernardo VG; Pires AR; da Fonseca EC; de Faria PA; da Silva LE; Geller M; de Moura-Neto RS; Lopes VS
J Clin Pathol; 2009 Jul; 62(7):629-33. PubMed ID: 19318344
[TBL] [Abstract][Full Text] [Related]
11. Expression of P53, P27 and KI-67 in colorectal cancer patients of various ethnic origins: clinical and tissue microarray based analysis.
Cohen T; Prus D; Shia J; Abu-Wasel B; Pinto MG; Freund HR; Stojadinovic A; Grakov A; Peretz T; Nissan A
J Surg Oncol; 2008 Apr; 97(5):416-22. PubMed ID: 18286523
[TBL] [Abstract][Full Text] [Related]
12. Semi-quantitative scoring of potentially predictive markers for endocrine treatment of breast cancer: a comparison between whole sections and tissue microarrays.
Henriksen KL; Rasmussen BB; Lykkesfeldt AE; Møller S; Ejlertsen B; Mouridsen HT
J Clin Pathol; 2007 Apr; 60(4):397-404. PubMed ID: 16775123
[TBL] [Abstract][Full Text] [Related]
13. Basal cytokeratin expression in relation to biological factors in breast cancer.
Kuroda H; Ishida F; Nakai M; Ohnisi K; Itoyama S
Hum Pathol; 2008 Dec; 39(12):1744-50. PubMed ID: 18755493
[TBL] [Abstract][Full Text] [Related]
14. Expression and prognostic significance of metalloproteases and their inhibitors in luminal A and basal-like phenotypes of breast carcinoma.
González LO; Corte MD; Junquera S; González-Fernández R; del Casar JM; García C; Andicoechea A; Vázquez J; Pérez-Fernández R; Vizoso FJ
Hum Pathol; 2009 Sep; 40(9):1224-33. PubMed ID: 19439346
[TBL] [Abstract][Full Text] [Related]
15. Head and neck squamous cell carcinoma in non-smoking and non-drinking patients with multiple tumors: etiologic significance of p53 and Ki-67 in non-tumorous epithelium.
Farshadpour F; Hordijk GJ; Koole R; Slootweg PJ
J Oral Pathol Med; 2008 Oct; 37(9):549-54. PubMed ID: 18331287
[TBL] [Abstract][Full Text] [Related]
16. Correlations of proliferation markers, p53 expression and histological findings in colorectal carcinoma.
Georgescu CV; Săftoiu A; Georgescu CC; Ciurea R; Ciurea T
J Gastrointestin Liver Dis; 2007 Jun; 16(2):133-9. PubMed ID: 17592558
[TBL] [Abstract][Full Text] [Related]
17. RET finger protein expression in invasive breast carcinoma: relationship between RFP and ErbB2 expression.
Tezel GG; Uner A; Yildiz I; Guler G; Takahashi M
Pathol Res Pract; 2009; 205(6):403-8. PubMed ID: 19232840
[TBL] [Abstract][Full Text] [Related]
18. [Expression of annexin I in different histological types of carcinomas].
Xue LY; Teng LH; Zou SM; Ren LQ; Zheng S; Luo W; Bi R; Lü N
Zhonghua Zhong Liu Za Zhi; 2007 Jun; 29(6):444-8. PubMed ID: 17974280
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of Ki-67 and p53 as tumor markers in salivary gland malignancies in Finland: an evaluation of 212 cases.
Luukkaa H; Klemi P; Leivo I; Vahlberg T; Grénman R
Acta Oncol; 2006; 45(6):669-75. PubMed ID: 16938809
[TBL] [Abstract][Full Text] [Related]
20. Automated quantitative analysis of estrogen receptor expression in breast carcinoma does not differ from expert pathologist scoring: a tissue microarray study of 3,484 cases.
Turbin DA; Leung S; Cheang MC; Kennecke HA; Montgomery KD; McKinney S; Treaba DO; Boyd N; Goldstein LC; Badve S; Gown AM; van de Rijn M; Nielsen TO; Gilks CB; Huntsman DG
Breast Cancer Res Treat; 2008 Aug; 110(3):417-26. PubMed ID: 17912629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]